Glenmark settles with Janssen on Ortho Tri-Cyclen Lo for launch alongside Teva, Watson
This article was originally published in Scrip
Executive Summary
Glenmark expects to launch norgestimate and ethinyl estradiol tablets, a generic version of Janssen Pharmaceuticals' oral contraceptive Ortho Tri-Cyclen Lo, in the US at the end of 2015, following a settlement of pending litigation with the Johnson & Johnson company.